SENSEI BIOTHERAPEUTICS INC (SNSE) Stock Overview
NASDAQ:SNSE - US81728A2078 - Common Stock
SNSE Key Statistics, Chart & Performance
The current stock price of SNSE is 8.355 USD. In the past month the price increased by 11.7%. In the past year, price decreased by -31.04%.
SNSE Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.87 | 371.68B | ||
| AMGN | AMGEN INC | 13.19 | 154.89B | ||
| GILD | GILEAD SCIENCES INC | 14.6 | 140.17B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.08 | 100.25B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.72 | 61.55B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 58.53B | ||
| ARGX | ARGENX SE - ADR | 76.83 | 43.59B | ||
| ONC | BEONE MEDICINES LTD-ADR | 6.16 | 36.38B | ||
| INSM | INSMED INC | N/A | 28.77B | ||
| BNTX | BIONTECH SE-ADR | N/A | 24.04B | ||
| NTRA | NATERA INC | N/A | 23.09B | ||
| BIIB | BIOGEN INC | 8.26 | 19.38B |
Related stock screener links
About SNSE
Company Profile
Sensei Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company which focuses on the discovery, development, and delivery of next generation immunotherapies for the treatment of cancer and infectious diseases. The company is headquartered in Rockville, Maryland and currently employs 14 full-time employees. The company went IPO on 2021-02-04. Through its Tumor Microenvironment Activated biologics (TMAb) platform, the Company develops conditionally active therapeutics designed to disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment to unleash T cells against tumors. Its lead investigational candidate is SNS-101, a conditionally active antibody designed to block the V-domain Ig suppressor of T cell activation checkpoint selectively within the low pH tumor microenvironment. The company is also developing SNS-102, a conditionally active monoclonal antibody targeting V-Set and Immunoglobulin Domain Containing 4 (VSIG-4); SNS-103, a conditionally active monoclonal antibody targeting ecto-nucleoside triphosphate diphosphohydrolase-1 (ENTPDase1), CD39; and SNS-201, a conditionally active VISTAxCD28 bispecific antibody.
Company Info
SENSEI BIOTHERAPEUTICS INC
1405 Research Blvd, Suite 125
Rockville MARYLAND 20850 US
CEO: John Celebi
Employees: 15
Phone: 12402438000
SENSEI BIOTHERAPEUTICS INC / SNSE FAQ
What is the stock price of SENSEI BIOTHERAPEUTICS INC today?
The current stock price of SNSE is 8.355 USD. The price increased by 4.18% in the last trading session.
What is the ticker symbol for SENSEI BIOTHERAPEUTICS INC stock?
The exchange symbol of SENSEI BIOTHERAPEUTICS INC is SNSE and it is listed on the Nasdaq exchange.
On which exchange is SNSE stock listed?
SNSE stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for SENSEI BIOTHERAPEUTICS INC stock?
9 analysts have analysed SNSE and the average price target is 68.85 USD. This implies a price increase of 724.06% is expected in the next year compared to the current price of 8.355. Check the SENSEI BIOTHERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is SENSEI BIOTHERAPEUTICS INC worth?
SENSEI BIOTHERAPEUTICS INC (SNSE) has a market capitalization of 10.53M USD. This makes SNSE a Nano Cap stock.
How many employees does SENSEI BIOTHERAPEUTICS INC have?
SENSEI BIOTHERAPEUTICS INC (SNSE) currently has 15 employees.
What are the support and resistance levels for SENSEI BIOTHERAPEUTICS INC (SNSE) stock?
SENSEI BIOTHERAPEUTICS INC (SNSE) has a support level at 8.12 and a resistance level at 8.69. Check the full technical report for a detailed analysis of SNSE support and resistance levels.
Should I buy SENSEI BIOTHERAPEUTICS INC (SNSE) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of SNSE, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of SNSE, evaluating the profitability, health, valuation and growth aspects
- SENSEI BIOTHERAPEUTICS INC (SNSE) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- SENSEI BIOTHERAPEUTICS INC (SNSE) Sales and EPS estimates to see what analysts future expectations are.
- SENSEI BIOTHERAPEUTICS INC (SNSE) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- SENSEI BIOTHERAPEUTICS INC (SNSE) Insider and Institutional Ownership to learn about the owners and their transactions.
- SENSEI BIOTHERAPEUTICS INC (SNSE) Stock Chart to make your own analysis
- SENSEI BIOTHERAPEUTICS INC (SNSE) Latest news and press-releases to stay up to date.
Does SENSEI BIOTHERAPEUTICS INC (SNSE) stock pay dividends?
SNSE does not pay a dividend.
When does SENSEI BIOTHERAPEUTICS INC (SNSE) report earnings?
SENSEI BIOTHERAPEUTICS INC (SNSE) will report earnings on 2025-11-12.
What is the Price/Earnings (PE) ratio of SENSEI BIOTHERAPEUTICS INC (SNSE)?
SENSEI BIOTHERAPEUTICS INC (SNSE) does not have a PE ratio as the earnings reported over the last twelve months were negative (-21.31).
What is the Short Interest ratio of SENSEI BIOTHERAPEUTICS INC (SNSE) stock?
The outstanding short interest for SENSEI BIOTHERAPEUTICS INC (SNSE) is 0.96% of its float. Check the ownership tab for more information on the SNSE short interest.
SNSE Technical Analysis
ChartMill assigns a technical rating of 6 / 10 to SNSE. When comparing the yearly performance of all stocks, SNSE turns out to be only a medium performer in the overall market: it outperformed 47.51% of all stocks.
SNSE Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to SNSE. While SNSE seems to be doing ok healthwise, there are quite some concerns on its profitability.
SNSE Financial Highlights
Over the last trailing twelve months SNSE reported a non-GAAP Earnings per Share(EPS) of -21.31. The EPS increased by 9.7% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -84.39% | ||
| ROE | -98.2% | ||
| Debt/Equity | 0 |
SNSE Forecast & Estimates
9 analysts have analysed SNSE and the average price target is 68.85 USD. This implies a price increase of 724.06% is expected in the next year compared to the current price of 8.355.